The Alzheimer's disease drug development landscape.

Pieter van BokhovenArno de WildeLisa Vermunt Prisca S LeferinkSasja HeetveldJeffrey CummingsPhilip ScheltensEverard G B Vijverberg

Published in: Alzheimer's research & therapy (2021)

Our observations show that the AD drug development pipeline is diversifying in terms of targets and treatment modalities, while amyloid-targeting therapies remain a prominent avenue of development as well. To further advance AD drug development, novel companion diagnostics are needed that are directed at disease mechanisms related to genetic risk factors of AD, both for patient stratification and assessment of therapeutic efficacy in clinical trials.

Keyphrases

risk factors
clinical trial
genome wide
gene expression
cancer therapy
cognitive decline
open label
drug induced
replacement therapy
copy number